Publications: 2022

Haas, D. W., Mngqibisa, R., Francis, J., McIlleron, H., Robinson, J. A., Kendall, M. A., Baker, P., Mawlana, S., Badal-Faesen, S., Angira, F., Omoz-Oarhe, A., Samaneka, W. P., Denti, P., & Cohn, S. E. (2022). Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis. Pharmacogenetics and Genomics, 32(1), 24–30. https://doi.org/10.1097/FPC.0000000000000448

Tikiso, T., McIlleron, H., Burger, D., Gibb, D., Rabie, H., Lee, J., Lallemant, M., Cotton, M. F., Archary, M., Hennig, S., & Denti, P. (2022). Abacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medications. British Journal of Clinical Pharmacology, 88(2), 403–415. https://doi.org/10.1111/BCP.14984

Griesel, R., Kawuma, A. N., Wasmann, R., Sokhela, S., Akpomiemie, | Godspower, Francois Venter, | W D, Lubbe Wiesner, |, Denti, P., Sinxadi, | Phumla, & Maartens, G. (2022). Concentration–response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy. British Journal of Clinical Pharmacology, 88(3), 883–893. https://doi.org/10.1111/BCP.15177

Denti, P., Wasmann, R. E., Francis, J., McIlleron, H., Sugandhi, N., Cressey, T. R., Mirochnick, M., Capparelli, E. V., & Penazzato, M. (2022). One dose does not fit all: revising the WHO paediatric dosing tool to include the non-linear effect of body size and maturation. The Lancet Child and Adolescent Health, 6(1), 9–10. https://doi.org/10.1016/S2352-4642(21)00302-3

Cindi, Z., Kawuma, A. N., Maartens, G., Bradford, Y., Venter, F., Sokhela, S., Chandiwana, N., Wasmann, R. E., Denti, P., Wiesner, L., Ritchie, M. D., Haas, D. W., & Sinxadi, P. (2022). Pharmacogenetics of Dolutegravir Plasma Exposure Among Southern Africans With Human Immunodeficiency Virus. The Journal of Infectious Diseases. https://doi.org/10.1093/INFDIS/JIAC174

Denti, P., Wasmann, R. E., van Rie, A., Winckler, J., Bekker, A., Rabie, H., Hesseling, A. C., van der Laan, L. E., Gonzalez-Martinez, C., Zar, H. J., Davies, G., Wiesner, L., Svensson, E. M., & McIlleron, H. M. (2021). Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study. Clinical Infectious Diseases. https://doi.org/10.1093/CID/CIAB908

van Rhee, K. P., Smit, C., Wasmann, R. E., van der Linden, P. D., Wiezer, R., Van Dongen, E. P. A., Krekels, E. H. J., Brüggemann, R. J. M., & Knibbe, C. A. J. (2022). Ciprofloxacin Pharmacokinetics After Oral and Intravenous Administration in (Morbidly) Obese and Non-obese Individuals: A Prospective Clinical Study. Clinical Pharmacokinetics, 61(8), 1167–1175. https://doi.org/10.1007/s40262-022-01130-5

Chen, L., Van Rhee, K. P., Wasmann, R. E., Krekels, E. H. J., Wiezer, M. J., Van Dongen, E. P. A., Verweij, P. E., Van Der Linden, P. D., Brüggemann, R. J., & Knibbe, C. A. J. (2022). Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults. Journal of Antimicrobial Chemotherapy, 77(8), 2217–2226. https://doi.org/10.1093/JAC/DKAC160

Kawuma, A. N., Wasmann, R. E., Dooley, K. E., Boffito, M., Maartens, G., & Denti, P. (2022). Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin. Antimicrobial Agents and Chemotherapy, 66(6). https://doi.org/10.1128/aac.00215-22

Gebreyesus, M. S., Decloedt, E. H., Cluver, C. A., Hunfeld, N. G. M., Helgadóttir, H., Björnsson, E. S., Wasmann, R. E., & Denti, P. (2022). Population pharmacokinetics of esomeprazole in patients with preterm preeclampsia. British Journal of Clinical Pharmacology, 88(10), 4639–4645. https://doi.org/10.1111/BCP.15416

Perumal, R., Arodola-Oladoyinbo, O., Naidoo, A., Kawuma, A. N., Naidoo, K., Gengiah, T. N., Chirehwa, M., Padayatchi, N., & Denti, P. (2022). Altered drug exposures of first-line TB drugs in a moxifloxacin-containing treatment regimen. The International Journal of Tuberculosis and Lung Disease : The Official Journal of the International Union against Tuberculosis and Lung Disease, 26(8), 766–774. https://doi.org/10.5588/IJTLD.21.0702

Griesel, R., Sinxadi, P., Kawuma, A., Joska, J., Sokhela, S., Akpomiemie, G., Venter, F., Denti, P., Haas, D. W., & Maartens, G. (2022). Pharmacokinetic and pharmacogenetic associations with dolutegravir neuropsychiatric adverse events in an African population. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/JAC/DKAC290